CLINICAL INVESTIGATIONS IN HODGKINS DISEASE

霍奇金病的临床研究

• 批准号: 6150114
• 负责人: SANDRA J. HORNING
• 金额: $ 25.64万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-02-07 至 2002-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6150114
• 关键词: Hodgkin's disease; adolescence (12-20); adult human (21+); cancer complication; cancer information system; cancer risk; child (0-11); clinical research; combination cancer therapy; drug administration rate /duration; drug adverse effect; human morbidity; human subject; human therapy evaluation; longitudinal human study; minimal residual disease; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; outcomes research; pediatric neoplasm /cancer; quality of life; radiation therapy dosage

It is the objective of these studies to improve the treatment outcomes for patients with newly diagnosed Hodgkin's disease and to continue to monitor the late effects of treatment on adults and children participating in past and present clinical trials. We intend to accomplish these goals through the conduct of novel therapeutic studies and the maintenance of a database on over 2500 Hodgkin's disease patients. The proposed clinical studies build upon our previous research efforts in Hodgkin's disease. A novel treatment for adults with early stage disease has been designed to maintain high cure rates, limit staging, and reduce late effects. This treatment, which consists of just eight weeks of chemotherapy followed by lower dose, modified involved field irradiation, is based on the success of abbreviated chemotherapy and limited irradiation in advanced stage disease. We plan to continue to study the abbreviated chemotherapy program, Stanford U, alone or in combination with irradiation in unfavorable and advanced stage Hodgkin's disease. Preliminary data indicate that this treatment approach is highly effective and, to date, has not been associated with serious morbidity. In the adult studies we plan to incorporate potentially more sensitive nuclear imaging for the identification of Hodgkin's disease and assessing the risk for relapse following the described treatments. Similar to adults, children with Hodgkin's disease will be treated according to risk group on clinical trials conducted at Stanford University, St. Jude Children's Research Hospital and the Dana Farber Cancer Center. Those patients with favorable, limited disease will receive four cycles of chemotherapy and low dose irradiation while an alternating chemotherapy program and low dose irradiation will be used for patients with unfavorable or advanced disease. Follow-on studies are planned for each of the clinical trials in progress in adults and children. An integral part of this application is the continued follow up of patients enrolled on prospective clinical trials at Stanford University since 1962. This includes the description of relapses, subsequent therapies, late morbidity, fatal treatment complications, causes of death and survival in over 2500 treated patients. These data, which have allowed Stanford investigators to make seminal observations on late effects such as second malignancy and cardiac disease, are maintained in a sophisticated database, representing a national resource for the efficacy and complications of the treatment of Hodgkin's disease.

这些研究的目的是改善治疗 新诊断为霍奇金氏病的患者的结果 继续监测治疗对成人和 参加过去和现在的临床试验的孩子。我们 打算通过新颖的行为来实现这些目标 治疗研究和维护2500多个数据库 霍奇金病患者。拟议的临床研究构建 在我们先前在霍奇金氏病方面的研究工作。小说 针对早期疾病的成年人的治疗已被设计为 保持较高的治愈率，限制分期并减少迟到的影响。 这种治疗方法仅包括八周的化学疗法 其次是较低剂量，修饰的涉及现场照射，为 基于缩写化疗的成功和有限 晚期疾病的辐照。我们计划继续学习 缩写的化学疗法计划，斯坦福大学，单独或 在不利和高级阶段的辐射结合 霍奇金氏病。初步数据表明这种处理 方法非常有效，迄今为止尚未关联 有严重的发病率。在成人研究中，我们计划合并 可能更敏感的核成像以识别 霍奇金氏病并评估复发的风险 描述的治疗方法。与成年人类似，有 霍奇金病将根据风险组的治疗 在圣裘德的斯坦福大学进行的临床试验 儿童研究医院和Dana Farber癌症中心。 那些有利，有限疾病的患者将接受四名 化学疗法和低剂量照射的周期 交替的化学疗法计划和低剂量照射将是 用于患有不利或晚期疾病的患者。跟进 计划对正在进行的每个临床试验进行研究 成人和儿童。此应用程序的一个不可或缺的一部分是 继续跟进前瞻性临床的患者 自1962年以来在斯坦福大学进行审判。这包括 复发的描述，随后的疗法，晚期发病率， 致命的治疗并发症，死亡原因和生存 2500名治疗患者。这些数据，允许斯坦福 调查人员对晚期作用进行开创性观察，例如 第二种恶性肿瘤和心脏病在 复杂的数据库，代表国家资源 霍奇金病治疗的功效和并发症。